(NewsDirect)
In the interest ofprotecting shareholders, GMedical Innovations Holdings Ltd . (NASDAQ: GMVD) announced that ithas investigated aggressive naked short sales of its stock and isconfident that it has identified the perpetrators of this illegalactivity. The company will defend its shareholders by taking allregulatory and legal action against this criminal activity. It hasinstructed its legal department to contact the SEC, FINRA, and NASDAQto conduct full investigations on their ends.
G Medical continues todemonstrate growth and commitment to expansion across its businessunits. Its wholly owned subsidiary, G Medical Tests and Services, Inc.as well as G-Medical Lab Services Inc. , continues to processthousands of COVID-19 PCR and rapid antigen/flu tests from its sitesand is prepared for increased testing capacity, given new virusvariants expected to emerge.
In addition, G Medical Innovations is involved innegotiations with numerous hospitals and healthcare systems for salesof its Prizma Care remotepatient monitoring devices and services. Patients, cardiologists, andhealth providers across the country rely on G Medical’s innovativePrizma monitoring devices and services for accurate and reliableremote monitoring.
The company is planning a shareholder’s conference callsoon. At that time, it will report on achievements during Q12022.
About G MedicalInnovations
GMedical Innovations Holdings Ltd. is an early commercial-stagehealthcare company engaged in the development of next-generationmHealth and telemedicine solutions and monitoring service platforms.The Company’s solutions and services can empower consumers,patients, and providers to better monitor, manage and improve clinicaland personal health outcomes, especially for those who suffer fromcardiovascular disease (or CVD), pulmonary disease, and diabetes. TheCompany’s current product lines consist of its Prizma medical device(or Prizma), a clinical-grade device that can transform almost anysmartphone into a medical monitoring device, enabling both healthcareproviders and individuals to monitor, manage and share a wide range ofvital signs and biometric indicators; its Extended Holter PatchSystem, a multi-channel patient-worn biosensor that captureselectrocardiography (or ECG) data continuously, including its QTSyndrome Prolongation Detection Capabilities Patch. In addition, theCompany is developing its Wireless Vital Signs Monitoring System (orVSMS), which is expected to provide full, continuous, and real-timemonitoring of a wide range of vital signs and biometrics. Itsmonitoring services include provision of Independent DiagnosticTesting Facility (or IDTF) monitoring services and private monitoringservices. Visit https://gmedinnovations.com/ .
Forward-LookingStatements
This press releasecontains forward-looking statements within the meaning of the “safeharbor” provisions of the Private Securities Litigation Reform Actof 1995 and other Federal securities laws. Words such as“expects,” “anticipates,” “intends,” “plans,”“believes,” “seeks,” “estimates,” and similar expressionsor variations of such words are intended to identify forward-lookingstatements. For example, G Medical is using forward-looking statementswhen it discusses that it continues to process thousands of COVID-19PCR and rapid antigen/flu tests from its sites and is prepared forincreased testing capacity, given new virus variants expected toemerge. Because such statements deal with future events and are basedon G Medical’s and McDade Products’ current expectations, they aresubject to various risks and uncertainties, and actual results,performance, or achievements of G Medical and McDade Products coulddiffer materially from those described in or implied by the statementsin this press release. The forward-looking statements contained orimplied in this press release are subject to other risks anduncertainties, including those discussed under the heading “RiskFactors” in G Medical’s prospectus filed pursuant to Rule424(b)(4), filed with the Securities and Exchange Commission(“SEC”) on June 28, 2021, the registration statement on Form F-1filed on February 14, 2022 (registration no. 333-262724) and in anysubsequent filings with the SEC. Except as otherwise required by law,the companies undertakes no obligation to publicly release anyrevisions to these forward-looking statements to reflect events orcircumstances after the date hereof or to reflect the occurrence ofunanticipated events. References and links to websites have beenprovided as a convenience, and the information contained on suchwebsites is not incorporated by reference into this press release. GMedical and McDade Products are not responsible for the contents ofthird-party websites.
Contact Details
KobiBen-Efraim, CFO
+972 8-958-4777
CompanyWebsite
Copyright (c) 2022 TheNewswire - All rights reserved.